Simon He

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 818 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial

Meletios Α. Dimopoulos, Francesca Gay, Fredrik Schjesvold et al. · The Lancet · 2018 · 236 citations · Full text

Medicine, Hematology, Pharmacotherapy +15

Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

Samantha J. Busfield, Mark Biondo, M. Wong et al. · Leukemia · 2014 · 148 citations · Full text

Medicine, Cancer Biology, Oncology +13

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia

Simon He, Samantha J. Busfield, Mark Hertzberg et al. · Leukemia & lymphoma/Leukemia and lymphoma · 2014 · 124 citations

Pharmacy, Clinical Pharmacokinetics, Pharmacology +16

Sorafenib plus intensive chemotherapy in newly diagnosed <i>FLT3</i>-ITD AML: a randomized, placebo-controlled study by the ALLG

Sun Loo, Andrew W. Roberts, Natasha S. Anstee et al. · Blood · 2023 · 30 citations · Full text

Medicine, Oncology, Pharmacology +16